MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

PLoS Medicine

Volumn 3, Issue 7, 2006, Pages 1140-1151

  Pikman, Yana ^a   Lee, Benjamin H ^a   Mercher, Thomas ^a   McDowell, Elizabeth ^a   Ebert, Benjamin L ^b,c   Gozo, Maricel ^a   Cuker, Adam ^a   Wernig, Gerlinde ^a   Moore, Sandra ^a   Galinsky, Ilene ^b   DeAngelo, Daniel J ^b   Clark, Jennifer J ^b   Lee, Stephanie J ^b   Golub, Todd R ^b,c,d   Wadleigh, Martha ^b   Gilliland, D Gary ^a,b,d   Levine, Ross L ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ERYTHROPOIETIN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; JANUS KINASE 2; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN; STAT5 PROTEIN; THROMBOPOIETIN RECEPTOR; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; CYTOKINE; CYTOKINE RECEPTOR; FIP1L1 PDGFRA FUSION PROTEIN, HUMAN; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; HYBRID PROTEIN; JANUS KINASE; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE INHIBITOR; STAT PROTEIN;

ANIMAL CELL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DNA SEQUENCE; EXON; EXTRAMEDULLARY HEMATOPOIESIS; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HYPERSENSITIVITY; IN VITRO STUDY; MOUSE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ORAL BIOPSY; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPLENOMEGALY; THROMBOCYTOSIS; WILD TYPE; AMINO ACID SUBSTITUTION; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; CELL CULTURE; CELL DIVISION; CLONOGENIC ASSAY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSCRIPTION; GENETICS; HEMATOLOGIC DISEASE; HEMATOPOIESIS; MEGAKARYOCYTE; MISSENSE MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; POINT MUTATION; PROTEIN PROCESSING; SPLEEN;

AMINO ACID SUBSTITUTION; ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL DIVISION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC VECTORS; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HUMANS; JANUS KINASES; MEGAKARYOCYTES; MICE; MICE, INBRED BALB C; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION, MISSENSE; MYELOID CELLS; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; POINT MUTATION; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTORS, CYTOKINE; RECOMBINANT FUSION PROTEINS; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SPLEEN; STAT TRANSCRIPTION FACTORS; THROMBOCYTOSIS; TRANSCRIPTION, GENETIC;

EID: 33746437130     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030270     Document Type: Article

References (36)

1. Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6: 372-375.
2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397.
3. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, et al. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106: 2162-2168.
4. James C, Ugo V, Le Couedic JP, StaERK J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148.
5. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
6. Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-1790.
7. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, et al. (2006) X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis. Blood 107: 4139-41.
8. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, et al. (2005) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107: 2098-2100.
9. Zhao R, Xing S, Li Z, Fu X, Li Q, et al. (2005) Identification of an Acquired JAK2 Mutation in Polycythemia Vera. J Biol Chem 280: 22788-22792.
10. Lu X, Levine R, Tong W, Wernig G, Pikman Y, et al. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 102: 18962-18967.
11. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, et al. (2006) Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107: 4274-4281.
12. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, et al. (2005) The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 106:2920-2921.
13. Taksin AL, Couedic JP, Dusanter-Fourt I, Masse A, Giraudier S, et al. (1999) Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 93: 125-139.
14. Le Couedic JP, Mitjavila MT, Villeval JL, Feger F, Gobert S, et al. (1996) Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood 87: 1502-1511.
15. Hess G, Rose P, Gamm H, Papadileris S, Huber C, et al. (1994) Molecular analysis of erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol 88: 794-802.
16. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214.
17. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, et al. (2002) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99: 310-318.
18. Stover EH, Chen J, Lee BH, Cools J, McDowell E, et al. (2005) The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 106: 3206-3213.
19. Growney JD, Shigematsu H, Li Z, Lee BH, Adelsperger J, et al. (2005) Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106: 494-504.
20. (2003) The International HapMap Project. Nature 426: 789-796.
21. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, et al. (2002) Photochemical preparation of a pyridone containing tetracycle: A Jak protein kinase inhibitor. Bioorg Med Chem Lett 12: 1219-1223.
22. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, et al. (2004) Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103: 4198-4200.
23. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC (1998) An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 18: 49-52.
24. Abe M, Suzuki K, Inagaki O, Sassa S, Shikama H (2002) A novel MPL point mutation resulting in thrombopoietin-independent activation. Leukemia 16: 1500-1506.
25. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, et al. (2005) An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood 107: 1864-1871.
26. Tefferi A (2005) Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 23: 8520-8530.
27. Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255-1265.
28. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, et al. (2000) STAT5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6: 693-704.
29. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, et al. (2003) PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 3: 459-469.
30. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830.
31. Kakumitsu H, Kamezaki K, Shimoda K, Karube K, Haro T, et al. (2005) Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res 29: 761-769.
32. Villeval JL, Cohen-Solal K, Tulliez M, Giraudier S, Guichard J, et al. (1997) High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90: 4369-4383.
33. Yan XQ, Lacey D, Fletcher F, Hartley C, McElroy P, et al. (1995) Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 86:4025-4033.
34. Vannucchi AM, Bianchi L, Cellai C, Paoletti F, Rana RA, et al. (2002) Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood 100: 1123-1132.
35. Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, et al. (2004) Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial. J Clin Oncol 22: 424-431.
36. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, et al. (2003) Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102: 3912-3918.